Streetbeat News

CADL

Candel Therapeutics, Inc.

https://www.candeltx.com

Industry

Biotechnology

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Open

5.14

Mkt cap

155M

Volume

416K

High

5.15

P/E Ratio

-2.98

52-wk high

14.30

Low

4.83

Div yield

N/A

52-wk low

0.77

Candel Therapeutics announced that the FDA has granted Orphan Drug Designation to its oncolytic viral immunotherapy, CAN-3110, for the treatment of recurrent high-grade glioma.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:04 pm

The article highlights significant intraday movements in health care stocks on Monday. Notable gainers include Innovative Eyewear (LUCY), OneMedNet (ONMD), Qilian Intl Hldg Gr (QLI), Onconetix (ONCO), TransCode Therapeutics (RNAZ), and MultiPlan (MPLN). Major losers include Verastem (VSTM), Sensei Biotherapeutics (SNSE), Genelux (GNLX), Candel Therapeutics (CADL), Exicure (XCUR), and HOOKIPA Pharma (HOOK).

Portfolio Pulse from Benzinga Insights

May 27, 2024 | 4:31 pm

The article highlights the pre-market movements of various health care stocks on Monday. Notable gainers include Cue Health (HLTH), SCWorx (WORX), Innovative Eyewear (LUCY), Vaccinex (VCNX), Guardant Health (GH), and Scinai Immunotherapeutics (SCNI). Significant losers include Verastem (VSTM), Sensei Biotherapeutics (SNSE), Genelux (GNLX), Summit Therapeutics (SMMT), Akari Therapeutics (AKTX), and Candel Therapeutics (CADL).

Portfolio Pulse from Benzinga Insights

May 27, 2024 | 12:05 pm

NetEase, Inc. (NASDAQ:NTES) shares fell 4% after reporting worse-than-expected first-quarter revenue. Despite a 7.2% year-on-year revenue growth to $3.72 billion, it missed the analyst consensus estimate of $3.79 billion. However, the company's adjusted EPADS of $1.81 beat the consensus estimate of $1.79. Other stocks moving significantly include Akanda Corp. (NASDAQ:AKAN), OneMedNet Corporation (NASDAQ:ONMD), and Verastem, Inc. (NASDAQ:VSTM).

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 5:57 pm

Ross Stores, Inc. (NASDAQ:ROST) shares surged over 8% in pre-market trading after reporting better-than-expected earnings and raising its profit forecast. The company posted quarterly revenue of $4.858 billion and earnings of $1.46 per share, surpassing estimates. Other notable pre-market movers include Netcapital Inc. (NASDAQ:NCPL), Akanda Corp. (NASDAQ:AKAN), and Workday, Inc. (NASDAQ:WDAY).

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 12:22 pm

Candel Therapeutics is set to present data from its Phase 2 clinical trial of CAN-2409 at the American Society of Clinical Oncology (ASCO). The treatment has shown a favorable safety and tolerability profile in non-small cell lung cancer (NSCLC) as of the data cut-off date.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:32 pm

NEXTracker Inc. (NASDAQ:NXT) reported better-than-expected Q4 earnings, leading to a 7.7% rise in its stock price. Other notable gainers include monday.com Ltd. (NASDAQ:MNDY), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Nu Holdings Ltd. (NYSE:NU), among others.

Portfolio Pulse from Avi Kapoor

May 15, 2024 | 2:22 pm

Candel Therapeutics (NASDAQ:CADL) reported a Q1 EPS loss of $(0.28), marking a 6.67% improvement from the $(0.30) per share loss reported in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:30 pm

Candel Therapeutics (NYSE:CADL) has seen a 7.89% increase in its short percent of float, now at 0.82% of all shares available for trading. With 160 thousand shares sold short, it would take about 4.49 days to cover these positions. This rise in short interest indicates a more bearish market sentiment towards CADL, although it has less short interest compared to its peers, with the average being 8.28%. The increase in short interest doesn't necessarily predict a price drop but suggests traders are betting more on a decline.

Portfolio Pulse from Benzinga Insights

April 19, 2024 | 4:00 pm

Fastenal Company's shares dropped by around 7% due to disappointing Q1 FY24 financial results, with sales and EPS missing consensus estimates. Other stocks experienced significant movements, with Rallybio Corporation, Rent the Runway, and Eliem Therapeutics among the top gainers, while Aptevo Therapeutics, Enlivex Therapeutics, and AVITA Medical led the losers.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 5:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.